AKI Therapeutics A/S: Financial statements 2019
CVR: 37509736
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
AKI Therapeutics A/S (CVR 37509736) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -127,150 and a net result of DKK 27,968 compared with DKK -4,608 the year before. Equity in the 2019 report amounted to DKK 52,395. The solvency ratio was 5.6%.
- Gross Profit
- DKK -127,150
- Profit/Loss
- DKK 27,968
- Equity
- DKK 52,395
- Total Assets
- DKK 933,411
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -127K | 28K | 52K | - |
| 2018 | - | -5K | -5K | 24K | - |
| 2017 | - | -4K | -13K | 29K | - |
| 2016 | - | -7K | -8K | 42K | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of November 17, 2019, NIELS ERIK JESPERSEN HOLDING ApS is registered as an owner of AKI Therapeutics A/S with an ownership share of 5%.
On September 13, 2019, the company changed its name from Renoguard ApS to AKI Therapeutics ApS.
AKI Therapeutics A/S has published its annual report for 2018. Gross profit came to DKK -4,600, and the net result was DKK -4,608.
About AKI Therapeutics A/S
AKI Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named AKI Therapeutics ApS and Renoguard ApS. The management consists of Sigbjørn Georg Nielsen Kjærgård. The board consists of Charlotte Pahl, Christian Vinding Thomsen and Lars Otto Uttenthal. The company's owners include NIELS ERIK JESPERSEN HOLDING ApS, Beier Holding ApS and FINANSMANAGEMENT ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -1,593,852,000 compared with DKK -1,960,091 the year before. Equity in the 2025 report amounted to DKK 551,898,000.